Cargando…

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies

BACKGROUND: Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR(12)). The incidence of EOT+/SVR in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malespin, Miguel, Benyashvili, Tamara, Uprichard, Susan L., Perelson, Alan S., Dahari, Harel, Cotler, Scott J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330612/ https://www.ncbi.nlm.nih.gov/pubmed/28286560 http://dx.doi.org/10.1177/1756283X16672392

Ejemplares similares

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017)

HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics
por: Durso-Cain, Karina, et al.
Publicado: (2021)

Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance
por: Shekhtman, Louis, et al.
Publicado: (2021)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Accounting for Space — Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models
por: Kumberger, Peter, et al.
Publicado: (2018)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
por: Shekhtman, Louis, et al.
Publicado: (2020)

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago
por: Echevarria, Desarae, et al.
Publicado: (2015)

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
por: Nada, Ali, et al.
Publicado: (2020)

Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum
por: Kushner, Tatyana, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection
por: Canini, Laetitia, et al.
Publicado: (2017)

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
por: Chen, Ruoyang, et al.
Publicado: (2021)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
por: Rong, Libin, et al.
Publicado: (2013)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir improves HCV‐induced insulin resistance by blocking IRS1 degradation
por: Rey, Esther, et al.
Publicado: (2021)

Permissiveness of human hepatoma cell lines for HCV infection
por: Sainz, Bruno, et al.
Publicado: (2012)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
por: Goyal, Ashish, et al.
Publicado: (2022)

Potential treatment options and future research to increase hepatitis C virus treatment response rate
por: TenCate, Veronica, et al.
Publicado: (2010)

Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes
por: Graw, Frederik, et al.
Publicado: (2014)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
por: Reinharz, Vladimir, et al.
Publicado: (2017)

The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir
por: Wu, Cheng-Kun, et al.
Publicado: (2022)

Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
por: Havens, Joshua P., et al.
Publicado: (2020)

Hepatocellular Carcinoma in a non-Cirrhotic Liver of a HCV-Positive Woman with Sustained Viral Response
por: Nosotti, L., et al.
Publicado: (2011)

Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
por: Hershkovich, Leeor, et al.
Publicado: (2023)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis
por: Khan, Mohammad Qasim, et al.
Publicado: (2017)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5641iqn609pe70rhl12k7lmn59